ASND
Ascendis Pharma A/S
There isn't enough reported data to score ASND yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ASND Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Under pressure | |
| Strong |
ASND's profitability and balance sheet are currently healthy, but its cash flow is under pressure. There isn't enough data to rate its revenue.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ASND PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $267 | — |
| Cheap | 22x | $313 | +17% |
| Fair | 27x | $388 | +45% |
| Expensive | 29x | $428 | +60% |
Historical ranges are pointers, not guarantees.
ASND's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ASND Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
ASND has the edge over HIMS on the outlook, with more favorable earnings and profitability expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ASND Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $14.54 | +$18.78 |
| Q4 2025 | -$4.18 | +$3.07 |
| Q3 2025 | -$4.24 | +$4.05 |
| Q2 2025 | -$5.04 | +$4.54 |
| Q1 2025 | -$6.45 | +$3.41 |
| Q4 2024 | -$7.25 | +$2.25 |
| Q3 2024 | -$8.29 | +$3.61 |
| Q2 2024 | -$9.58 | +$2.49 |
ASND has the stronger earnings trend. Trailing diluted EPS is up 125% for ASND versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ASND Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +347% |
| Q4 2025 | $274.9M | +42% |
| Q3 2025 | $237.3M | +269% |
| Q2 2025 | $175.6M | +339% |
| Q1 2025 | $112.1M | +5.3% |
| Q4 2024 | $193.2M | +26% |
| Q3 2024 | $64.2M | +20% |
| Q2 2024 | $40M | -24% |
ASND has the stronger quarterly revenue trend. Revenue is up 847% for ASND versus up 49% for HIMS.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 39% | +142 points |
| Q4 2025 | 4% | +3.8 points |
| Q3 2025 | 5.2% | +172 points |
| Q2 2025 | -34% | +337 points |
| Q1 2025 | -103% | -52 points |
| Q4 2024 | 0.2% | +27 points |
| Q3 2024 | -167% | +113 points |
| Q2 2024 | -370% | -73 points |
ASND has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ASND Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2024 | -$62.9M | +$76.8M |
| Q2 2024 | -$68.5M | +$102.1M |
| Q1 2024 | -$113.1M | +$51.5M |
| Q4 2023 | -$47.1M | +$114.5M |
| Q3 2023 | -$139.6M | -$26.3M |
| Q2 2023 | -$170.6M | -$28.3M |
| Q1 2023 | -$164.6M | -$15M |
| Q4 2022 | -$161.6M | -$19.3M |
ASND has the stronger cash trend. Its trailing FCF is up 36% versus its history, compared with HIMS at down 84%.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ASND Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +10% | +6.2M shares |
| 1 year | +11% | +6.8M shares |
| 3 years | +19% | +10.7M shares |
| 5 years | +24% | +13M shares |
| Available history | +42% | +19.6M shares |
ASND has 67M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $173.1M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $19.3M |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $2,222 |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ASND on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ASND Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.5x | Net Cash |
ASND has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ASND Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.3 | Neutral |
| Stochastic | 73.4 | Neutral |
ASND's weekly RSI is 59 (neutral) and its Stochastic is 73 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ASND PE vs Healthcare Sector
| Metric | ASND | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 26x | 29% below |
| PE % | 4 | 29 | 25 pts below |
ASND is trading at 18x earnings, a 29% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ASND Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $240.8 | 11% above |
| 20 week MA | $250.3 | 6.7% above |
| 50 week MA | $235.2 | 14% above |
| 100 week MA | $202.9 | 32% above |
| 200 week MA | $160.1 | 67% above |
ASND has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ASND Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $135.1 | $170.9 | +27% |
| 2021 | $170.9 | $139.3 | -18% |
| 2022 | $139.3 | $119.1 | -15% |
| 2023 | $119.1 | $126.0 | +5.8% |
| 2024 | $126.0 | $137.5 | +9.2% |
| 2025 | $137.5 | $209.0 | +52% |
| 2026 YTD | $209.0 | $267.1 | +28% |
ASND has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.